180 related articles for article (PubMed ID: 37498552)
1. Discovery of Novel 1,2,3,4-Tetrahydrobenzofuro[2,3-
Lai Z; Ni H; Hu X; Cui S
J Med Chem; 2023 Aug; 66(15):10791-10807. PubMed ID: 37498552
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.
Wong JC; Tang G; Wu X; Liang C; Zhang Z; Guo L; Peng Z; Zhang W; Lin X; Wang Z; Mei J; Chen J; Pan S; Zhang N; Liu Y; Zhou M; Feng L; Zhao W; Li S; Zhang C; Zhang M; Rong Y; Jin TG; Zhang X; Ren S; Ji Y; Zhao R; She J; Ren Y; Xu C; Chen D; Cai J; Shan S; Pan D; Ning Z; Lu X; Chen T; He Y; Chen L
J Med Chem; 2012 Oct; 55(20):8903-25. PubMed ID: 23061376
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Novel Dual Histone Deacetylase and Mammalian Target of Rapamycin Target Inhibitors as a Promising Strategy for Cancer Therapy.
Chen Y; Yuan X; Zhang W; Tang M; Zheng L; Wang F; Yan W; Yang S; Wei Y; He J; Chen L
J Med Chem; 2019 Feb; 62(3):1577-1592. PubMed ID: 30629434
[TBL] [Abstract][Full Text] [Related]
4. Design, Synthesis and Biological Evaluation of Novel Coumarin-Based Hydroxamate Derivatives as Histone Deacetylase (Hdac) Inhibitors with Antitumor Activities.
Yang F; Zhao N; Song J; Zhu K; Jiang CS; Shan P; Zhang H
Molecules; 2019 Jul; 24(14):. PubMed ID: 31311163
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
Jiang BE; Hu J; Liu H; Liu Z; Wen Y; Liu M; Zhang HK; Pang X; Yu LF
Eur J Med Chem; 2022 Jan; 227():113893. PubMed ID: 34656899
[TBL] [Abstract][Full Text] [Related]
6. Hydroxamic acid derivatives as HDAC1, HDAC6 and HDAC8 inhibitors with antiproliferative activity in cancer cell lines.
Sixto-López Y; Gómez-Vidal JA; de Pedro N; Bello M; Rosales-Hernández MC; Correa-Basurto J
Sci Rep; 2020 Jun; 10(1):10462. PubMed ID: 32591593
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening.
Liu J; Zhou J; He F; Gao L; Wen Y; Gao L; Wang P; Kang D; Hu L
Eur J Med Chem; 2020 Apr; 192():112189. PubMed ID: 32151834
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.
Yang Z; Shen M; Tang M; Zhang W; Cui X; Zhang Z; Pei H; Li Y; Hu M; Bai P; Chen L
Eur J Med Chem; 2019 Sep; 178():116-130. PubMed ID: 31177073
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
Xie R; Yao Y; Tang P; Chen G; Liu X; Yun F; Cheng C; Wu X; Yuan Q
Eur J Med Chem; 2017 Jul; 134():1-12. PubMed ID: 28391133
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel polysubstituted
Wang Z; Zhao L; Zhang B; Feng J; Wang Y; Zhang B; Jin H; Ding L; Wang N; He S
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2206581. PubMed ID: 37144599
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and anti-tumor activity study of novel histone deacetylase inhibitors containing isatin-based caps and o-phenylenediamine-based zinc binding groups.
Gao S; Zang J; Gao Q; Liang X; Ding Q; Li X; Xu W; Chou CJ; Zhang Y
Bioorg Med Chem; 2017 Jun; 25(12):2981-2994. PubMed ID: 28511906
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological or transcriptional inhibition of both HDAC1 and 2 leads to cell cycle blockage and apoptosis via p21
Zhou H; Cai Y; Liu D; Li M; Sha Y; Zhang W; Wang K; Gong J; Tang N; Huang A; Xia J
Cell Prolif; 2018 Jun; 51(3):e12447. PubMed ID: 29484736
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
Tavares MT; de Almeida LC; Kronenberger T; Monteiro Ferreira G; Fujii de Divitiis T; Franco Zannini Junqueira Toledo M; Mariko Aymoto Hassimotto N; Agostinho Machado-Neto J; Veras Costa-Lotufo L; Parise-Filho R
Bioorg Med Chem; 2021 Apr; 35():116085. PubMed ID: 33668008
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of novel hybrids targeting mTOR and HDACs for potential treatment of hepatocellular carcinoma.
Zhai S; Zhang H; Chen R; Wu J; Ai D; Tao S; Cai Y; Zhang JQ; Wang L
Eur J Med Chem; 2021 Dec; 225():113824. PubMed ID: 34509167
[TBL] [Abstract][Full Text] [Related]
15. Design and Synthesis of Fibroblast Growth Factor Receptor (FGFR) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Cancer.
Wan G; Feng Z; Zhang Q; Li X; Ran K; Feng H; Luo T; Zhou S; Su C; Wei W; Wang N; Gao C; Zhao L; Yu L
J Med Chem; 2022 Dec; 65(24):16541-16569. PubMed ID: 36449947
[TBL] [Abstract][Full Text] [Related]
16. HDAC inhibition activates the apoptosome via Apaf1 upregulation in hepatocellular carcinoma.
Buurman R; Sandbothe M; Schlegelberger B; Skawran B
Eur J Med Res; 2016 Jun; 21(1):26. PubMed ID: 27342975
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells.
Buurman R; Gürlevik E; Schäffer V; Eilers M; Sandbothe M; Kreipe H; Wilkens L; Schlegelberger B; Kühnel F; Skawran B
Gastroenterology; 2012 Sep; 143(3):811-820.e15. PubMed ID: 22641068
[TBL] [Abstract][Full Text] [Related]
18. Development of hydroxamate-based histone deacetylase inhibitors containing 1,2,4-oxadiazole moiety core with antitumor activities.
Yang F; Shan P; Zhao N; Ge D; Zhu K; Jiang CS; Li P; Zhang H
Bioorg Med Chem Lett; 2019 Jan; 29(1):15-21. PubMed ID: 30455152
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
Xie R; Li Y; Tang P; Yuan Q
Eur J Med Chem; 2018 Jan; 143():320-333. PubMed ID: 29202397
[TBL] [Abstract][Full Text] [Related]
20. A novel HDAC1 inhibitor, CBUD‑1001, exerts anticancer effects by modulating the apoptosis and EMT of colorectal cancer cells.
Kim SL; La MT; Shin MW; Kim SW; Kim HK
Int J Oncol; 2020 Oct; 57(4):1027-1038. PubMed ID: 32945468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
